Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Raphaël Hurtubise
Observed names:
R. Hurtubise,
Raphael Hurtubise
Institutions:
Centre Hospitalier de l’Université de Montréal,
Université de Montréal
Observed institutions:
Nuffield Orthopaedic Centre,
Hôpital Maisonneuve-Rosemont,
University of Oxford,
Centre Hospitalier de l’Université de Montréal,
Université de Montréal
ORCID:
0000-0003-4155-2963
Observed ORCID:
0000-0003-4155-2963
OpenAlex ID:
A5064666359
Induced and spontaneous colitis mouse models reveal complex interactions between IL-10 and IL-12/IL-23 pathways
2019
·
Raphaël Hurtubise
, Cindy Audiger
, et al.
·
Cytokine
·
11
OP0089 Early intensive therapy with combination csDMARDs or TNF inhibitors are superior to standard step up care for the treatment of moderate to severe psoriatic arthritis: the 3-arm parallel group SPEED RCT.
2025
·
S. Massa
, E. Saeedi
, et al.
·
Annals of the Rheumatic Diseases
·
7
Association between gastroprotective agents and risk of incident interstitial lung disease in systemic sclerosis
2021
·
Raphaël Hurtubise
, Marie Hudson
, et al.
·
Respiratory Medicine
·
5
P.109 Prognostic value of quantitative chest computed tomography for predicting progression of mild interstitial lung disease in systemic sclerosis: a multicentric nested case-control study
2026
·
Sabrina Hoa
, Marcelo Veiga Da Silva
, et al.
·
Poster presentations
P.108 Predicting progression of mild interstitial lung disease in systemic sclerosis: an international retrospective cohort study
2026
·
Sabrina Hoa
, Danick Goulet
, et al.
·
Poster presentations
Real-World Treat-to-Target Strategy in Psoriatic Arthritis: 48-week Results from the MONITOR-PsA Cohort
2026
·
Jean-Guillaume Letarouilly
, Elnaz Saeedi
, et al.
·
SSRN Electronic Journal
Stratégie du traitement à la cible dans le rhumatisme psoriasique en vraie vie : résultats à 48 semaines de la cohorte MONITOR-PsA
2025
·
J.G. Letarouilly
, S. Elnaz
, et al.
·
Revue du Rhumatisme
POS0106 REAL-WORLD TREAT-TO-TARGET STRATEGY IN PSORIATIC ARTHRITIS: 48-WEEK RESULTS FROM THE MONITOR-PsA COHORT
2025
·
J.G. Letarouilly
, E. Saeedi
, et al.
·
Annals of the Rheumatic Diseases
OP0093 Effectiveness of Combination csDMARD Therapy in Psoriatic Arthritis Using Data from the MONITOR-PsA Cohort
2025
·
R. Hurtubise
, J.G. Letarouilly
, et al.
·
Annals of the Rheumatic Diseases
Impact of disease manifestations on first biologic drug survival in axial spondyloarthritis: a real-life Canadian study
2024
·
Raphaël Hurtubise
, Sherry Rohekar
, et al.
·
Rheumatology Advances in Practice
PDF
Pos0811 Impact of Disease Manifestations on First Biologic Drug Survival in Axial Spondyloarthritis: a Real-world Canadian Study
2024
·
R. Hurtubise
, S. Rohekar
, et al.
·
Annals of the Rheumatic Diseases
Show more works
View as search
Works count:
11
Citation count:
23
H-index:
3
I10-index:
1
Year
Topic
Type